PALO ALTO, Calif.--(BUSINESS WIRE)--LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on treating diseases with few or no therapeutic options, today announced the appointment of Laman Alani, Ph.D., to the position of VP, Product Development. In this role, Dr. Alani will be responsible for and provide strategic leadership to all aspects of CMC development for the entire pipeline portfolio. LifeMax has two clinical stage assets including LM-030 for the treatment of Netherton Syndrome.
“We are very excited to welcome Dr. Laman Alani into our senior leadership. Dr. Alani brings tremendous experience from both small and large companies. Her in-depth expertise and successful track records across multiple dosage forms bode very well with our portfolio,” said Larry Hsu, LifeMax’s Co-founder and CEO, an industry veteran who previously founded and built Impax Laboratories into a publicly traded multi-billion dollar company.
“I am much delighted to work with the LifeMax management team again. LifeMax has built a robust and diverse pipeline, and it’s an exciting time to be onboard. I look forward to working with the team to advance the development of our portfolio,” said Dr. Alani.
Dr. Laman Alani is a biotech and pharmaceutical industry leader with close to 30 years of experience at companies including Alcon, Merck, Novartis, Impax, Abbott and Pfizer. Over the span of her career, she has led the CMC development for more than 20 successful drug products across a wide range of dosage forms, is an inventor to over 40 patents, and developed long term R&D strategy in partnership with senior management. Dr. Alani received her Ph.D. in medicinal chemistry from University of Kansas.
About LifeMax Laboratories Inc.
LifeMax Laboratories, Inc. (www.lifemaxlabs.com), a wholly-owned subsidiary of LifeMax Healthcare International Corporation (www.lifemaxhealthcare.com), is a clinical-stage biotech company focused on treating diseases with few or no therapeutic options. LifeMax is applying its expertise and in-depth experience with drug development and commercialization to advance its well-balanced portfolio of products addressing critical unmet medical needs. It has recently closed a Series A round of $25 million.